ProfileGDS5678 / 1440169_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 91% 89% 88% 90% 88% 90% 90% 89% 89% 88% 88% 88% 89% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.2961191
GSM967853U87-EV human glioblastoma xenograft - Control 27.0694789
GSM967854U87-EV human glioblastoma xenograft - Control 36.9422288
GSM967855U87-EV human glioblastoma xenograft - Control 47.3634390
GSM967856U87-EV human glioblastoma xenograft - Control 56.8612688
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.9720190
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.0446990
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.919689
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.955989
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8782688
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.8496688
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.9330888
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.0723189
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.6155787